2021 Program: 7th Update on Fabry Disease:
Biomarkers, Progression and Treatment Opportunities
May 30-June 1, 2021: Würzburg Germany
Supporting Organization: Kidneys for Life (Manchester, UK)
Secretariat:
Venue:
Program Steering Committee:
Carla E. M. Hollak, MD PhD, AMC, Universiteit van Amsterdam, Amsterdam NZ
Derralyn Hughes, Royal Free Hospital, London UK
Albina Nowak, MD, University of Zurich, Zurich CH
Raphael Schiffmann, Baylor Scott & White Research Institute, Dallas TX USA
Andrew Talbot, Royal Melbourne Hospital, Melbourne AU
Stephen Waldek, Sunderland University UK
Christoph Wanner, University of Würzburg, Würzburg Germany
David G. Warnock, University of Alabama at Birmingham, USA
Michael West, Dalhousie University, Nova Scotia, Canada
This educational activity is supported by unrestricted medical education grants from:
Major Sponsors:
Sponsors:
The 1st Fabry Nephropathy Satellite "Focus on Fabry Nephropathy: Biomarkers, Progression and Disease Severity", an Official Satellite of the World Congress of Nephrology, was held in Bergamo Italy in May 2009. The second Fabry Nephropathy Satellite "Focus on Fabry Nephropathy: Biomarkers, Progression and Treatment Opportunities" was organized as an Official Satellite of the World Congress of Nephrology, and was held in Vancouver, Canada on April 12--14, 2011. The 3rd Update on Fabry Nephropathy was held in conjunction with the World Congress of Nephrology, in Hong Kong on June 4-5, 2013. The 4th Fabry Nephropathy Update was a Satellite of the ERA_EDTA 2015 Meeting, and was held in Manchester, UK on June 1-2, 2015. The 5th Fabry Nephropathy Update was an official Satellite of the 2017 ISN WCN Meeting, and was held in Mexico City, Mexico on April 25-27, 2017. The 7th Update on Fabry Disease was held in Prague, CZ, May 26-28, 2019. The 7th Update on Fabry Disease will be held May 30-June1, 2021 in Würzburg Germany
The 3-day conference features, state of the art plenary presentations, structured debates and poster presentations. The intended audience are content experts and "treaters" of Fabry Disease. The focus will be on emerging treatment approaches, baseline characteristics that determine the patient-specific responses to the treatment of Fabry disease, and antibody interactions with infused enzyme replacement therapy.
PROGRAM